List view / Grid view
Inauguration of the new facility supports BeiGene’s goal to develop…
Inauguration of the new facility supports BeiGene’s goal to develop affordable and accessible cancer treatments for patients globally.
Approval of BeiGene’s TEVIMBRA® (tislelizumab) in EU follows an agreement…
Approval of BeiGene’s TEVIMBRA® (tislelizumab) in EU follows an agreement with Novartis to regain global rights of the antibody treatment.
The marketing agent for China, BeiGene, announced the China National…
The marketing agent for China, BeiGene, announced the China National Medical Products Administration (NMPA) suspended the importation, sales and use of ABRAXANE.
The mAb tislelizumab has been granted approval from Chinese authorities,…
The mAb tislelizumab has been granted approval from Chinese authorities, making Boehringer Ingelheim Biopharmaceuticals the first MAH under the new system.
